Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to Buy at Wall Street Zen

Key Points

• Kiniksa Pharmaceuticals International was downgraded from a "strong-buy" to a "buy" rating by Wall Street Zen, reflecting a shift in analyst sentiment towards the stock.
• Despite the downgrade, seven analysts still maintain a Buy rating for Kiniksa, with an average target price of $44.29, suggesting potential upside from current levels.
• The company's recent quarterly earnings exceeded expectations, with a reported EPS of $0.23 against a consensus estimate of $0.18, indicating robust financial performance.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a note issued to investors on Friday.

KNSA has been the subject of several other reports. Wedbush reissued an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Weiss Ratings reissued a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a report on Saturday, September 27th. TD Cowen initiated coverage on shares of Kiniksa Pharmaceuticals International in a report on Monday. They set a "buy" rating and a $60.00 target price on the stock. Wells Fargo & Company upped their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an "overweight" rating in a research report on Thursday, September 25th. Finally, Jefferies Financial Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of "Moderate Buy" and an average target price of $44.29.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA traded up $1.02 during trading on Friday, hitting $38.49. The stock had a trading volume of 608,856 shares, compared to its average volume of 422,627. Kiniksa Pharmaceuticals International has a 12 month low of $17.82 and a 12 month high of $39.12. The company's 50-day moving average price is $34.49 and its two-hundred day moving average price is $28.66. The company has a market capitalization of $2.85 billion, a PE ratio of 962.49 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 17,000 shares of the stock in a transaction on Monday, August 4th. The stock was sold at an average price of $32.35, for a total transaction of $549,950.00. Following the transaction, the chief accounting officer owned 33,041 shares in the company, valued at $1,068,876.35. This trade represents a 33.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Eben Tessari sold 138,614 shares of the business's stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $33.20, for a total transaction of $4,601,984.80. Following the completion of the sale, the chief operating officer directly owned 49,915 shares of the company's stock, valued at approximately $1,657,178. The trade was a 73.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 603,371 shares of company stock worth $20,434,869 in the last 90 days. Corporate insiders own 53.48% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently made changes to their positions in KNSA. EverSource Wealth Advisors LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after acquiring an additional 532 shares during the period. Corebridge Financial Inc. increased its holdings in Kiniksa Pharmaceuticals International by 3.6% in the 1st quarter. Corebridge Financial Inc. now owns 15,979 shares of the company's stock valued at $355,000 after buying an additional 549 shares during the period. GAMMA Investing LLC raised its position in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after buying an additional 568 shares in the last quarter. Sound View Wealth Advisors Group LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 4.0% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock worth $326,000 after acquiring an additional 568 shares during the period. Finally, Martingale Asset Management L P boosted its position in shares of Kiniksa Pharmaceuticals International by 1.3% during the 1st quarter. Martingale Asset Management L P now owns 50,000 shares of the company's stock worth $1,111,000 after acquiring an additional 640 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.